Zacks Investment Research downgraded Merit Medical Systems, Inc. (NASDAQ:MMSI) to Hold in a report released today.
- Updated: September 27, 2016
Zacks Investment Research has downgraded Merit Medical Systems, Inc. (NASDAQ:MMSI) to Hold in a report released on 9/28/2016.
Previously on 7/19/2016, Canaccord Genuity reported on Merit Medical Systems, Inc. (NASDAQ:MMSI) increased the target price from $0.00 to $27.00. At the time, this indicated a possible upside of 0.27%.
Yesterday Merit Medical Systems, Inc. (NASDAQ:MMSI) traded 0.60% higher at $23.62. The company’s 50-day moving average is $24.02 and its 200-day moving average is $20.80. The last closing price is up 13.57% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 190,062 shares of the stock traded hands, down from an average trading volume of 272,475
See Chart Below
Merit Medical Systems, Inc. has a 52 week low of $15.47 and a 52 week high of $25.50 with a P/E ratio of 46.31 The company’s market cap is currently $0.
General Information About Merit Medical Systems, Inc. (NASDAQ:MMSI)
Merit Medical Systems, Inc. is a designer, developer, manufacturer and marketer of medical devices used in an array of interventional and diagnostic procedures. The Company operates in two segments: cardiovascular and endoscopy. Its cardiovascular segment consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases; embolotherapeutic products, and cardiac rhythm management and electrophysiology (CRM/EP) devices. Its endoscopy segment consists of gastroenterology and pulmonology medical devices, which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its products are used in various clinical areas, such as diagnostic and interventional cardiology; interventional radiology; vascular, general and thoracic surgery; interventional pulmonology; interventional nephrology; oncology, and pain management.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.